![](/media/kxhhdrhb/4_pipeline-v3.jpg?anchor=center&mode=crop&width=1920&height=1080&rnd=133052059425230000)
Pipeline
Advancing a novel product candidate for cardiometabolic disorders
Developing ninerafaxstat in three high value cardiometabolic indications.
Phase 2 clinical trials have been completed in non-obstructive hypertrophic cardiomyopathy (nHCM), stable angina, and early-stage heart failure with preserved ejection fraction (pre-HFpEF). We are currently recruiting HFpEF patients for IMPROVE-DiCE Part 2.
![](/media/cpjhtpaj/2024-02-07-pipeline.jpg)
![](/media/wcdn2lbm/imbria_images_microscope_detail.jpg?center=0.48669131024253454,0.3437647258766&mode=crop&width=960&height=1280&rnd=133028979500100000)